Skip to main content
OpenTrials
Completed

NCT Number: NCT00198796

Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains

Five subjects will be admitted to the General Clinical Research Center (GCRC). The next day they will eat a light breakfast, fast for 90 minutes, ingest ETEC strain H10407, and fast for 90 more minutes. After this challenge they will be monitored closely , and all stools will be collected, graded and weighed. On Day 5, or sooner if indicated, they will begin antibiotics to eradicate the challenge strain. They will be scheduled for discharge on Day 7 but may leave a few days earlier if early antibiotic treatment is given.

Hypothesis:

A challenge dose of 10(9) colony forming unit (CFU) of ETEC strain H10407, will cause diarrhea in at least 60% of subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

General Clinical Research Center

Baltimore, Maryland, 21205, United States

About this study

The rationale for validation H10407 in the challenge study proposed at Johns Hopkins University is that this initial challenge study will support additional challenge studies planned for the future. In these future studies, a bovine milk immunoglobulin containing high levels of antibodies specific for colonization factor antigen (CFA/I) or CFA/I-derived colonization factor will be investigated as a potential oral prophylaxis to neutralize subsequent challenge against CFA/I-expressing H10407 in the clinical setting. The goal here is therefore to validate a challenge dose of 1x109 h10407 organisms in the hands of the Johns Hopkins investigative team and to then use this dose in the future prophylaxis/challenge studies. Challenge doses equal to or comparable to the 1x109 dose proposed for the Johns Hopkins University (JHU) study have been used in 6 of the 9 challenge studies that have been done with the H10407 strain. The subsequent challenge studies using H10407 will be registered as part of other protocols.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults age 18 to 45 years old who are willing to participate, complete training on ETEC and diarrhea and procedures of the protocol, pass the test documenting knowledge of the study, and give informed consent.

Exclusion criteria

  • age<18 or >45 years
  • Chronic illness, chemical dependency, or significant medical illness as determined by the investigator.
  • immunosuppressive condition or IgA (Immunoglobulin A) deficiency
  • HIV antibody positive
  • hepatitis B surface antigen positive
  • hepatitis C antibody positive
  • travel to ETEC endemic area within 2 years
  • vaccination or other exposure to ETEC, cholera, or heat labile toxin (LT) toxin within 3 years
  • pregnancy as defined by + serum or urine - human chorionic gonadotropin (HCG) on the day before immunization
  • inability to pass the written examination
  • use of antibiotic, H2 blocking agent or proton pump inhibitor within 7 days of challenge
  • regular use of laxatives antacids or other agents to lower stomach acidity
  • significant abnormality in screening lav hematology and chemistry tests as determined by the investigator.
  • significant abnormality on EKG for those 40 to 50 years old as determined by the investigator.
  • allergy to quinolones, penicillin's and Bactrim.
  • abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day).

Treatment and study plan

H10407

Biological

The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea

Other names: Experimental

Primary outcomes

  1. To validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea, as determined by stool output volumes or signs and symptoms associated with hypovolemia.

    Time frame: 6 months

Secondary outcomes

  1. To measure mucosal and systemic immune response to the somatic and toxin antigens of the H10407 strain.

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Johns Hopkins Bloomberg School of Public Health

Other

Collaborators

  • Henry M. Jackson Foundation for the Advancement of Military Medicine
  • Naval Medical Research Center
  • U.S. Army Medical Research and Development Command
  • Walter Reed Army Institute of Research (WRAIR)

Registry information

Official study title

Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express Colonization Factors CS17 and CFA/I

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Sep 20, 2005
Registry last updated
Apr 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.